ReviewFrontiers in immunology2026
Macrophage-derived long non-coding RNAs in cancer: pioneering targets for immune modulation and personalized therapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generated from macrophages, long non-coding RNAs (lncRNAs) are increasingly recognized as imperative in influencing cancer immune evasion, microenvironment alteration, and therapy sensitivity. Together with tumor-associated macrophages (TAMs), this detailed investigation investigates the several roles of lncRNAs derived from M1 and M2 macrophage subtypes in regulating tumor progression. In contrast to the cancer-promoting effect of M2-based derived lncRNAs, such as H19, AFAP1-AS1, and CRNDE, which stimulate tumor proliferation, metastases, and chemoresistance through a variety of cascades, M1-based derived lncRNAs, such as HOTTIP and NBR2, exhibit tumor-suppressive roles in augmenting inflammatory signals and inhibiting epithelial-mesenchymal transition. Other than their involvement in the development of cancer, macrophage-derived lncRNAs have important immune control effects based on macrophage polarization, cytokine production, and immune checkpoints. Recent progress in single-cell RNA sequencing and the CRISPR-based functional studies also now provides new lncRNA targets and improved accuracy of diagnostics and optimization of therapy approaches. It marks a new step in personalized cancer immunotherapy: our research focuses on the possibilities of macrophage-derived lncRNAs as biomarkers and treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.